Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05257343 · ClinicalTrials.gov registry record · NA
Efficacy of a Low Dose, Oral, Liquid Iron Supplement on Restoring Inadequate Blood Iron to Normal Levels
A NA study, sponsored by Applied Science & Performance Institute.
- Completed
- Registry status
- NA
- Development phase
- 95
- Enrollment target
NCT05257343: Completed NA study, sponsored by Applied Science & Performance Institute.
NCT05257343 is a NA study that has completed, run by Applied Science & Performance Institute. The registered enrollment target is 95 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05257343, a NA study, has completed, sponsored by Applied Science & Performance Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 95 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled, 8-week intervention clinical study assessing the safety and efficacy of a new low-dose liquid iron supplement in restoring iron levels to normal ranges without promoting constipating side-effects among healthy premenopausal women with non-anemic iron deficiency. The primary outcomes will be an Iron Panel of Serum Iron, Ferritin, Total iron-binding capacity, Transferrin saturation, Complete Blood Count, and high sensitivity - C-Reactive Protein. Secondary outcomes will be surveys on gastrointestinal distress/discomfort and well-being. Adverse events will also be reported.
Primary Outcome
Changes in Iron in fasted serum blood samples.
Interventions
- DIETARY_SUPPLEMENT Liquid Placebo Supplementation
- DIETARY_SUPPLEMENT Liquid Iron Supplement (Blood Builder ®)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2022-02-07 |
| Est. Completion | 2022-12-09 |
| Phase | NA |
What the finished NCT05257343 record still lists
NCT05257343 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 95 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 2 interventions - of which Liquid Placebo Supplementation is the first listed.
NCT05257343 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05257343 about?
NCT05257343 is a clinical study titled "Efficacy of a Low Dose, Oral, Liquid Iron Supplement on Restoring Inadequate Blood Iron to Normal Levels". This is a randomized, double-blind, placebo-controlled, 8-week intervention clinical study assessing the safety and efficacy of a new low-dose liquid iron supplement in restoring iron levels to normal ranges without promoting constipating side-effects among healthy premenopausal women with non-anemi...
What is the current status of trial NCT05257343?
This trial is currently completed. It is a NA study. The enrollment target is 95 participants. The study started on 2022-02-07. Estimated completion is 2022-12-09.
What interventions are being tested in trial NCT05257343?
The interventions under investigation include: Liquid Placebo Supplementation (DIETARY_SUPPLEMENT), Liquid Iron Supplement (Blood Builder ®) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05257343?
This trial is sponsored by Applied Science & Performance Institute, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05257343's enrollment target sits among peer trials
95 931st of 2000 higher than 1,066 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03339128 · 95 participants · Phase 2
Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children
- NCT03509961 · 95 participants · Phase 2
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- NCT03694756 · 95 participants · NA
TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer
- NCT04206215 · 95 participants · NA
Noninvasive Brain Stimulation for Treating Carpal Tunnel Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI